Abstract:As a promising radiotherapy technology, stereotactic body radiotherapy (SBRT) enables precise delivery of high-dose radiation in a short course. The characteristic of SBRT is that a high dose outside the target area decreases rapidly, which can ensure the therapeutic dose of the target area and can also minimize the exposure dose of the organ at risk around the target area when compared with regular radiotherapy. Currently, SBRT has become an effective treatment for early stage NSCLC especially for older patients when they are not suitable for operation. We have read with interest this article by Moreno et al.1Moreno A.C. Fellman B. Hobbs B.P. et al.Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC.J Thorac Oncol. 2020; 15: 101-109Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar about the optimal dose for SBRT in patients with early NSCLC. Moreno et al.1Moreno A.C. Fellman B. Hobbs B.P. et al.Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC.J Thorac Oncol. 2020; 15: 101-109Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar investigated a large cohort with over 20,500 patients. They found that 5-year overall survival (OS) rates were 26% for low biologically effective dose (BED) (BED10 < 130 Gy) and 34% for high BED (BED10 ≥ 130 Gy) groups (p = 0.039), suggesting that a BED10 of 130 Gy and above may confer an additional survival benefit. We would like to point out some concerns regarding this article. First, the authors should consider the competitive risk relationship between cancer-caused death and noncancer-caused death, which is highly related to age. In this article, 70% of patients are more than 70 years old. Thus, noncancer-caused death could be the primary reason for the death toll. Second, we wonder whether the age range was well-balanced between the low-BED and high-BED groups, because the authors only divided patients into two groups (age <70 y and age ≥70 y). We believe that the authors should perhaps need to divide the age into more stratifications (such as <70 y, 75–80 y, 80–85 y, >85 y) or consider the age as a continuous variable in propensity-score matching. Recent studies revealed that SBRT, combined with other treatments, was associated with improved survival. Grinnell et al.2Grinnell M. Appiah A.K. Baine M. et al.Adjuvant chemotherapy following SBRT for early stage non-small cell lung cancer (NSCLC) in older patients [e-pub ahead of print]. J Geriatr Oncol.https://doi.org/10.1016/j.jgo.2020.04.014Google Scholar found adjuvant chemotherapy after SBRT was associated with improved OS in patients more than 70 years old with tumors greater than or equal to 4 cm2. SBRT and immune checkpoint inhibition are rapidly growing and effective treatment modalities.3Käsmann L. Eze C. Manapov F. Stereotactic body radiation therapy (SBRT) combined with immune check-point inhibition (ICI) in advanced lung cancer: which metastatic site should be irradiated to induce immunogenic cell death?.Int J Radiation Oncol Biol Phys. 2020; 108: 225-226Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar In the randomized phase 2 study (PEMBRO-RT) trial, compared with pembrolizumab, SBRT followed by pembrolizumab revealed a doubling of the OS (15.9 mo versus 7.6 mo) and objective response rate (36% versus 18%) in advanced NSCLCs.4Theelen W.S.M.E. Peulen H.M.U. Lalezari F. et al.Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial.JAMA Oncol. 2019; 5: 1276-1282Crossref PubMed Scopus (243) Google Scholar These combinations greatly expand the application range of SBRT. As the population ages, there will be a higher proportion of patients who are suitable for SBRT. Therefore, SBRT is a promising method for future clinical applications.

Partial Stereotactic Ablative Boost Radiation Therapy in Bulky Bladder/Urothelial Cancer

Partial Stereotactic Ablative Boost Radiotherapy in Bulky Non-Small Cell Lung Cancer: a Retrospective Study.

Partial Stereotactic Ablative Boost Radiation Therapy in Bulky Tumors - A Retrospective, Single Center's Experience

Clinical and Radiobiologic Effect of Partial Stereotactic Ablative Radiation Therapy in NSCLC

Partial Stereotactic Ablative Radiotherapy in Bulky Urinary Tract Malignancy: an Update Clinical Outcomes and Dosimetric Analysis

Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a dosimetric comparison between proton and photon

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer.

Clinical Outcome of CT-Guided Stereotactic Ablative Brachytherapy for Unresectable Early Non-Small Cell Lung Cancer: A Retrospective, Multicenter Study

Hypofractionated 192ir Source Stereotactic Ablative Brachytherapy with Coplanar Template Assistance in the Primary Treatment of Peripheral Lung Cancer.

Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer

Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas

Stereotactic Radiation Therapy in Early Non–Small Cell Lung Cancer and Interstitial Lung Disease

Patient, tumour, and dosimetric factors influencing survival in non-small cell lung cancer patients treated with stereotactic ablative body radiotherapy

CT-Guided Online Adaptive Radiotherapy Delivered via Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) for a Bulky Thoracic and Abdominal Mass in Oligometastatic Renal Cell Carcinoma

PUB114 Dose-Response Relationship for Safety and Efficacy Using Stereotactic Body Radiation Therapy for Centrally-Located Non-Small Cell Lung Cancer

High-dose-rate Three-dimensional Conformal Radiotherapy Combined with Active Breathing Control for Stereotactic Body Radiotherapy of Early-stage Non-small-cell Lung Cancer

Dosimetric Comparison of 192ir Sources Stereotactic Ablative Brachytherapy by Coplanar Template Assisted CT Guidance and Stereotactic Body Radiation Therapy in the Treatment of Early Stage Lung Cancer

Promising Stereotactic Body Radiotherapy in NSCLC

Dosimetric Comparison of Robotic Radiosurgery and VMAT Delivering Stereotactic Ablative Body Radiation Therapy to Small Renal Cancer

A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer

Hypofractionated Volumetric-Modulated Arc Radiotherapy for Patients With Non-Small-Cell Lung Cancer Not Suitable for Surgery or Conventional Chemoradiotherapy or SBRT